{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:04:02Z","timestamp":1787598242356,"version":"build-2736575974"},"reference-count":115,"publisher":"Georg Thieme Verlag KG","issue":"11","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is a debilitating recurrent inflammatory disease of the central nervous system. Establishing management guidelines is essential to optimize patient care in Brazil.<\/jats:p>\n                  <jats:p>To combine the Delphi and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approaches to validate evidence-based guideline statements for NMOSD treatment.<\/jats:p>\n                  <jats:p>These guidelines focused on providing recommendations for different scenarios: general management and diagnosis of NMOSD; acute and preventive treatments (including systemic immunosuppressants and anti-B cell, anti-interleukin-6, and anti-complement monoclonal antibodies); and therapeutic approaches in special groups (such as the pediatric population and pregnant women). A literature review based on the Population, Intervention, Comparator, and Outcome (PICO) framework was performed, and studies were evaluated using the GRADE system. An initial questionnaire containing 19 statements was sent to 44 specialists from all regions of Brazil.<\/jats:p>\n                  <jats:p>Three voting rounds were necessary to reach consensus in all statements. After the first voting round, 17 statements reached consensus (level of agreement\u2009&gt;\u200970%). Two statements failed to reach consensus and were, thus, revised. One of them was segmented into three different statements. After the second voting round, three out of the four revised statements reached consensus. Upon further revision, the last statement was again submitted to voting, reaching consensus in this third round. Overall, agreement was achieved on the 21 proposed statements.<\/jats:p>\n                  <jats:p>The primary objective in the management of NMOSD is to mitigate the severity of the attacks and prevent relapses, thereby minimizing the risk of irreversible neurological deficits. The statements in the current guideline offer evidence-based recommendations for such management within the Brazilian context.<\/jats:p>","DOI":"10.1055\/s-0045-1812471","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T01:19:37Z","timestamp":1762823977000},"page":"001-021","source":"Crossref","is-referenced-by-count":2,"title":["2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children"],"prefix":"10.1055","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-1199","authenticated-orcid":false,"given":"Samira Luisa dos","family":"Ap\u00f3stolos-Pereira","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Hospital das Cl\u00ednicas, Servi\u00e7o de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7919-3989","authenticated-orcid":false,"given":"Alfredo","family":"Damasceno","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0834-1056","authenticated-orcid":false,"given":"Ana Claudia","family":"Piccolo","sequence":"additional","affiliation":[{"name":"Universidade Municipal de S\u00e3o Caetano do Sul, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-6019","authenticated-orcid":false,"given":"Maria Fernanda","family":"Mendes","sequence":"additional","affiliation":[{"name":"Santa Casa de S\u00e3o Paulo, Faculdade de Ci\u00eancias M\u00e9dicas, Disciplina de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6136-4612","authenticated-orcid":false,"given":"Maria L\u00facia","family":"Brito","sequence":"additional","affiliation":[{"name":"Hospital da Restaura\u00e7\u00e3o, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1141-8619","authenticated-orcid":false,"given":"Regina","family":"Alvarenga","sequence":"additional","affiliation":[{"name":"Universidade Federal do Estado do Rio de Janeiro, P\u00f3s-Gradua\u00e7\u00e3o Stricto Sensu em Neurologia, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4752-2717","authenticated-orcid":false,"given":"Bruna Klein da","family":"Costa","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul, Porto Alegre RS, Brazil."},{"name":"Santa Casa de Porto Alegre, Hospital da Crian\u00e7a Santo Ant\u00f4nio, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-6020","authenticated-orcid":false,"given":"Douglas Kazutochi","family":"Sato","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre, Servi\u00e7o de Neurologia, Porto Alegre RS, Brazil."},{"name":"Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Departamento de Medicina Interna, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9050-3319","authenticated-orcid":false,"given":"Doralina Guimar\u00e3es","family":"Brum","sequence":"additional","affiliation":[{"name":"Universidade Estadual Paulista, Faculdade de Medicina de Botucatu, Botucatu SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-8277","authenticated-orcid":false,"given":"Elisa","family":"Mello","sequence":"additional","affiliation":[{"name":"Santa Casa de S\u00e3o Paulo, Faculdade de Ci\u00eancias M\u00e9dicas, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1004-7641","authenticated-orcid":false,"given":"Felipe","family":"von Glehn","sequence":"additional","affiliation":[{"name":"Universidade de Bras\u00edlia, Bras\u00edlia DF, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8949-6115","authenticated-orcid":false,"given":"Giordani","family":"Passos","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul, Hospital S\u00e3o Lucas, Porto Alegre RS, Brazil."},{"name":"Hospital M\u00e3e de Deus, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-3763","authenticated-orcid":false,"given":"Guilherme","family":"Diogo","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Hospital das Cl\u00ednicas, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1694-0457","authenticated-orcid":false,"given":"Herval","family":"Soares Neto","sequence":"additional","affiliation":[{"name":"Hospital do Servidor P\u00fablico Estadual de S\u00e3o Paulo, S\u00e3o Paulo SP, Brazil."},{"name":"Hospital Israelita Albert Einstein, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4456-2684","authenticated-orcid":false,"given":"Lis","family":"Campos","sequence":"additional","affiliation":[{"name":"Universidade Federal de Sergipe, Aracaj\u00fa SE, Brazil."},{"name":"Universidade Tiradentes, Aracaj\u00fa SE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9942-7649","authenticated-orcid":false,"given":"Manuela","family":"Fragomeni","sequence":"additional","affiliation":[{"name":"Hospital da Crian\u00e7a de Bras\u00edlia, Bras\u00edlia DF, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3298-0264","authenticated-orcid":false,"given":"Milena de Sales","family":"Pitombeira","sequence":"additional","affiliation":[{"name":"Hospital Geral de Fortaleza, Divis\u00e3o de Neurologia, Fortaleza CE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7649-0195","authenticated-orcid":false,"given":"Rafael","family":"Paterno","sequence":"additional","affiliation":[{"name":"Irmandade da Santa Casa de S\u00e3o Paulo, Servi\u00e7o de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-3413","authenticated-orcid":false,"given":"Raquel","family":"Vass\u00e3o","sequence":"additional","affiliation":[{"name":"Santa Casa de Belo Horizonte, Cl\u00ednica Neurol\u00f3gica, Belo Horizonte MG, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3548-8467","authenticated-orcid":false,"given":"Renata Barbosa","family":"Paolilo","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Hospital das Cl\u00ednicas, Instituto da Crian\u00e7a, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5008-2783","authenticated-orcid":false,"given":"Tarso","family":"Adoni","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Hospital das Cl\u00ednicas, Servi\u00e7o de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-4288","authenticated-orcid":false,"given":"Thiago","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia, Hospital Universit\u00e1rio Professor Edgar Santos, Salvador BA, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2131-9438","authenticated-orcid":false,"given":"Vanessa","family":"Daccach","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Hospital das Cl\u00ednicas, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9981-3620","authenticated-orcid":false,"given":"Jefferson","family":"Becker","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0833-4024","authenticated-orcid":false,"given":"Claudia Cristina Ferreira","family":"Vasconcelos","sequence":"additional","affiliation":[{"name":"Universidade Federal do Estado do Rio de Janeiro, P\u00f3s-Gradua\u00e7\u00e3o Stricto Sensu em Neurologia, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"D M Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide","volume":"11","author":"J Y Hor","year":"2020","journal-title":"Front Neurol"},{"issue":"02","key":"ref3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review","volume":"96","author":"V Papp","year":"2021","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"V A Lennon","year":"2004","journal-title":"Lancet"},{"issue":"09","key":"ref5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"P J Waters","year":"2012","journal-title":"Neurology"},{"issue":"06","key":"ref6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"D K Sato","year":"2014","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Y Wu","year":"2023","journal-title":"Mult Scler"},{"issue":"08","key":"ref8","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1177\/1352458518776584","article-title":"Treating neuromyelitis optica with azathioprine: 20-year clinical practice","volume":"25","author":"D B Bichuetti","year":"2019","journal-title":"Mult Scler"},{"issue":"05","key":"ref9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/wnl.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"D M Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"07","key":"ref10","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1002\/acn3.52092","article-title":"Characterizing mortality in patients with AQP4-Ab+ neuromyelitis optica spectrum disorder","volume":"11","author":"A Francis","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"issue":"02","key":"ref11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice","volume":"10","author":"M Royston","year":"2021","journal-title":"Neurol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"B AC Cree","year":"2019","journal-title":"Lancet"},{"issue":"06","key":"ref13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"93","author":"S J Pittock","year":"2023","journal-title":"Ann Neurol"},{"issue":"07","key":"ref14","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"S J Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"ref15","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"T Yamamura","year":"2019","journal-title":"N Engl J Med"},{"issue":"04","key":"ref16","doi-asserted-by":"publisher","first-page":"e200124","DOI":"10.1212\/NXI.0000000000200124","article-title":"International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab","volume":"10","author":"F Paul","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"106244","DOI":"10.1016\/j.msard.2024.106244","article-title":"Recommendations on NMOSD treatment in Latin America: Utilizing consensus-based RAND\/UCLA methodology","volume":"94","author":"R Alonso","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"04","key":"ref18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"H Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"457","key":"ref19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fpubh.2020.00457","article-title":"Delphi Technique in Health Sciences: A Map","volume":"8","author":"M Niederberger","year":"2020","journal-title":"Front Public Health"},{"issue":"01","key":"ref20","doi-asserted-by":"publisher","first-page":"2241234","DOI":"10.1080\/20016689.2023.2241234","article-title":"Rapid literature review: definition and methodology","volume":"11","author":"B Smela","year":"2023","journal-title":"J Mark Access Health Policy"},{"issue":"03","key":"ref21","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","article-title":"The well-built clinical question: a key to evidence-based decisions","volume":"123","author":"W S Richardson","year":"1995","journal-title":"ACP J Club"},{"issue":"03","key":"ref22","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"B G Weinshenker","year":"2006","journal-title":"Ann Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.msard.2018.01.001","article-title":"Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients","volume":"20","author":"E C Contentti","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"02","key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0045-1801845","article-title":"A roadmap to increasing access to AQP4-Ig testing for NMOSD: expert recommendations","volume":"83","author":"R Vass\u00e3o-Araujo","year":"2025","journal-title":"Arq Neuro-Psiquiatr"},{"issue":"04","key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211052656","article-title":"Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders","volume":"7","author":"V Redenbaugh","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"03","key":"ref26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"B Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"966428","DOI":"10.3389\/fneur.2022.966428","article-title":"The patient journey with NMOSD: From initial diagnosis to chronic condition","volume":"13","author":"G Delgado-Garcia","year":"2022","journal-title":"Front Neurol"},{"issue":"10","key":"ref28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1055\/s-0042-1754348","article-title":"Reducing infection risk in multiple sclerosis and neuromyelitis optica spectrum disorders: a Brazilian reference center's approach","volume":"80","author":"A BAGR Gomes","year":"2022","journal-title":"Arq Neuro-Psiquiatr"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.msard.2018.05.003","article-title":"Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"M A Mealy","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"01","key":"ref30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","article-title":"Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders","volume":"266","author":"G Ellrichmann","year":"2019","journal-title":"J Neurol"},{"issue":"01","key":"ref31","doi-asserted-by":"publisher","first-page":"e200071","DOI":"10.1212\/NXI.0000000000200071","article-title":"Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar","volume":"10","author":"I Kleiter","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"06","key":"ref32","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s10072-023-06676-1","article-title":"Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD","volume":"44","author":"S Kim","year":"2023","journal-title":"Neurol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"103394","DOI":"10.1016\/j.msard.2021.103394","article-title":"Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy?","volume":"58","author":"H Cai","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"02","key":"ref34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"H Abboud","year":"2016","journal-title":"Mult Scler"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3389\/fneur.2020.00932","article-title":"Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD","volume":"11","author":"T Akaishi","year":"2020","journal-title":"Front Neurol"},{"issue":"02","key":"ref36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40120-022-00344-w","article-title":"Efficacy of Plasma Exchange Treatment for Demyelinating Optic Neuritis Associated with Various Serum Antibodies: A Prospective Cohort Study","volume":"11","author":"J Fu","year":"2022","journal-title":"Neurol Ther"},{"issue":"04","key":"ref37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/aian.AIAN_365_19","article-title":"Plasma Exchange as a First Line Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorders","volume":"22","author":"B L Kumawat","year":"2019","journal-title":"Ann Indian Acad Neurol"},{"issue":"04","key":"ref38","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"M Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"578295","DOI":"10.1016\/j.jneuroim.2024.578295","article-title":"Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil","volume":"388","author":"GMRd Almeida","year":"2024","journal-title":"J Neuroimmunol"},{"issue":"06","key":"ref40","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions","volume":"5","author":"I Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"02","key":"ref41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"I Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"585471","DOI":"10.3389\/fneur.2020.585471","article-title":"Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder","volume":"11","author":"C Qin","year":"2020","journal-title":"Front Neurol"},{"issue":"03","key":"ref43","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1055\/s-0042-1758447","article-title":"Plasma exchange in inflammatory demyelinating disorders of the central nervous system: reasonable use in the clinical practice","volume":"81","author":"A LG Queiroz","year":"2023","journal-title":"Arq Neuro-Psiquiatr"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"102325","DOI":"10.1016\/j.msard.2020.102325","article-title":"Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD)","volume":"44","author":"X Li","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"03","key":"ref45","doi-asserted-by":"publisher","first-page":"e22129","DOI":"10.1002\/jca.22129","article-title":"Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add-on therapy in acute attacks of neuromyelitis optica spectrum disorder","volume":"39","author":"G Siwach","year":"2024","journal-title":"J Clin Apher"},{"issue":"04","key":"ref46","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"M Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"103730","DOI":"10.1016\/j.msard.2022.103730","article-title":"Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration","volume":"60","author":"M Tahara","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211056710","article-title":"Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"14","author":"H Wang","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"03","key":"ref49","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension","volume":"28","author":"S J Pittock","year":"2022","journal-title":"Mult Scler"},{"issue":"05","key":"ref50","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"A Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"06","key":"ref51","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","article-title":"Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial","volume":"23","author":"B AC Cree","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"105868","DOI":"10.1016\/j.msard.2024.105868","article-title":"Heterogenous relapse and efficacy endpoint definitions for neuromyelitis optica spectrum disorder studies: A systematic review","volume":"91","author":"R B Rocha","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pediatrneurol.2024.09.028","article-title":"Racial, Ethnic, and Socioeconomic Disparities in Pediatric Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"161","author":"K E Poisson","year":"2024","journal-title":"Pediatr Neurol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"104485","DOI":"10.1016\/j.msard.2022.104485","article-title":"Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort","volume":"70","author":"V Tkachuk","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"20","key":"ref55","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"M I Leite","year":"2012","journal-title":"Neurology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1528989","DOI":"10.3389\/fimmu.2024.1528989","article-title":"Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review","volume":"15","author":"X Song","year":"2025","journal-title":"Front Immunol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"104025","DOI":"10.1016\/j.msard.2022.104025","article-title":"Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar","volume":"66","author":"T Yamamura","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"105829","DOI":"10.1016\/j.msard.2024.105829","article-title":"Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan","volume":"90","author":"M Niino","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.18553\/jmcp.2022.28.12-a.s1","article-title":"Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder","volume":"28","author":"D M Wingerchuk","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"106160","DOI":"10.1016\/j.msard.2024.106160","article-title":"Early rituximab versus escalating therapy in neuromyelitis optica: A cost and quality of life analysis","volume":"92","author":"G D Silva","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"02","key":"ref61","doi-asserted-by":"publisher","first-page":"e0229028","DOI":"10.1371\/journal.pone.0229028","article-title":"Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis","volume":"15","author":"S Aungsumart","year":"2020","journal-title":"PLoS One"},{"issue":"07","key":"ref62","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"C Costanzi","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"ref63","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"L Elsone","year":"2014","journal-title":"Mult Scler"},{"issue":"09","key":"ref64","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Z Nikoo","year":"2017","journal-title":"J Neurol"},{"issue":"07","key":"ref65","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jocn.2015.01.028","article-title":"Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica","volume":"22","author":"W Qiu","year":"2015","journal-title":"J Clin Neurosci"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study","volume":"370","author":"Y Xu","year":"2016","journal-title":"J Neurol Sci"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Y Yang","year":"2018","journal-title":"J Neurol Sci"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"102750","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Y Takai","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"08","key":"ref69","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"S Watanabe","year":"2007","journal-title":"Mult Scler"},{"issue":"08","key":"ref70","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","article-title":"Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies","volume":"84","author":"J Kitley","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cen3.12189","article-title":"Methotrexate is effective for the treatment of neuromyelitis optica spectrum disorders in Asian patients","volume":"6","author":"A SL Ng","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"issue":"02","key":"ref72","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/WNF.0000000000000131","article-title":"The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China","volume":"39","author":"H Chen","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.3389\/fimmu.2018.02066","article-title":"Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China","volume":"9","author":"Q Huang","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"ref74","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"S Y Huh","year":"2014","journal-title":"JAMA Neurol"},{"issue":"09","key":"ref75","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"A Jacob","year":"2009","journal-title":"Arch Neurol"},{"issue":"01","key":"ref76","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12883-018-1056-x","article-title":"Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study","volume":"18","author":"Y Jiao","year":"2018","journal-title":"BMC Neurol"},{"issue":"03","key":"ref77","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"M A Mealy","year":"2014","journal-title":"JAMA Neurol"},{"issue":"10","key":"ref78","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"A Montcuquet","year":"2017","journal-title":"Mult Scler"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"103882","DOI":"10.1016\/j.msard.2022.103882","article-title":"The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients","volume":"63","author":"C Pathomrattanapiban","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"06","key":"ref80","first-page":"149","article-title":"Efficacy of mycophenolate mofetil for AQP4 antibody-positive optic neuritis immunotherapy","volume":"22","author":"Z YSF Zheng","year":"2022","journal-title":"International Eye Science."},{"issue":"08","key":"ref81","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1111\/ene.15355","article-title":"Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder","volume":"29","author":"W Huang","year":"2022","journal-title":"Eur J Neurol"},{"issue":"04","key":"ref82","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1007\/s10072-021-05609-0","article-title":"Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors","volume":"43","author":"L Zhang","year":"2022","journal-title":"Neurol Sci"},{"issue":"09","key":"ref83","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study","volume":"263","author":"P Annovazzi","year":"2016","journal-title":"J Neurol"},{"issue":"10","key":"ref84","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"G S Bedi","year":"2011","journal-title":"Mult Scler"},{"issue":"13","key":"ref85","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1177\/1352458517730131","article-title":"Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders","volume":"24","author":"M A Mealy","year":"2018","journal-title":"Mult Scler"},{"issue":"04","key":"ref86","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1212\/NXI.0000000000000046","article-title":"Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children","volume":"1","author":"G Longoni","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"05","key":"ref87","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"C Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"104315","DOI":"10.1016\/j.neuint.2018.10.012","article-title":"Blockade of IL-6 signaling in neuromyelitis optica","volume":"130","author":"M Araki","year":"2019","journal-title":"Neurochem Int"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"660230","DOI":"10.3389\/fimmu.2021.660230","article-title":"Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder","volume":"12","author":"C Du","year":"2021","journal-title":"Front Immunol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"101920","DOI":"10.1016\/j.msard.2019.101920","article-title":"Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders","volume":"39","author":"I Lotan","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"01","key":"ref91","doi-asserted-by":"publisher","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders","volume":"9","author":"M Ringelstein","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"05","key":"ref92","doi-asserted-by":"publisher","first-page":"e837","DOI":"10.1212\/NXI.0000000000000837","article-title":"Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study","volume":"7","author":"R B Paolilo","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"09","key":"ref93","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000201625","article-title":"Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder","volume":"100","author":"R P Umeton","year":"2023","journal-title":"Neurology"},{"issue":"02","key":"ref94","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3760\/cma.j.issn.0578-1310.2019.02.011","article-title":"[Clinical analysis of neuromyelitis optica spectrum disorders in childhood]","volume":"57","author":"J Zhou","year":"2019","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"02","key":"ref95","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children","volume":"71","author":"A McKeon","year":"2008","journal-title":"Neurology"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.msard.2018.07.036","article-title":"Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders","volume":"25","author":"M O Fragomeni","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fped.2020.00339","article-title":"Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis","volume":"8","author":"S Tenembaum","year":"2020","journal-title":"Front Pediatr"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"102252","DOI":"10.1016\/j.msard.2020.102252","article-title":"Pre-pregnancy, obstetric and delivery status in women with neuromyelitis optica spectrum disorder","volume":"44","author":"F Ashtari","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"15","key":"ref99","doi-asserted-by":"publisher","first-page":"e2006","DOI":"10.1212\/WNL.0000000000011744","article-title":"Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder","volume":"96","author":"N Collongues","year":"2021","journal-title":"Neurology"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"107342","DOI":"10.1016\/j.clineuro.2022.107342","article-title":"Exploring the association of reproductive history with the development and course of neuromyelitis optica spectrum disorder","volume":"219","author":"M Hadinejad","year":"2022","journal-title":"Clin Neurol Neurosurg"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jns.2016.11.054","article-title":"Pregnancy in neuromyelitis optica spectrum disorder: A multicenter study from South China","volume":"372","author":"Y Huang","year":"2017","journal-title":"J Neurol Sci"},{"issue":"08","key":"ref102","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/ene.14274","article-title":"Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder","volume":"27","author":"S H Kim","year":"2020","journal-title":"Eur J Neurol"},{"issue":"16","key":"ref103","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1212\/WNL.0b013e318250d812","article-title":"Influence of pregnancy on neuromyelitis optica spectrum disorder","volume":"78","author":"W Kim","year":"2012","journal-title":"Neurology"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jns.2017.03.051","article-title":"Effectiveness and safety of immunosuppressive therapy in neuromyelitis optica spectrum disorder during pregnancy","volume":"377","author":"B Shi","year":"2017","journal-title":"J Neurol Sci"},{"issue":"11","key":"ref105","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1177\/1352458515583376","article-title":"Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder","volume":"22","author":"Y Shimizu","year":"2016","journal-title":"Mult Scler"},{"issue":"12","key":"ref106","first-page":"1401","article-title":"Safety of azathioprine use during pregnancy","volume":"57","author":"A Natekar","year":"2011","journal-title":"Can Fam Physician"},{"issue":"12","key":"ref107","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1345\/aph.1H152","article-title":"Breast-feeding during maternal use of azathioprine","volume":"40","author":"M E Moretti","year":"2006","journal-title":"Ann Pharmacother"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.reprotox.2019.05.066","article-title":"Fetal methotrexate syndrome: A systematic review of case reports","volume":"87","author":"E A Verberne","year":"2019","journal-title":"Reprod Toxicol"},{"issue":"02","key":"ref109","doi-asserted-by":"publisher","first-page":"e034529","DOI":"10.1136\/bmjopen-2019-034529","article-title":"Differences in medication beliefs between pregnant women using medication, or not, for chronic diseases: a cross-sectional, multinational, web-based study","volume":"10","author":"S R Munoz","year":"2020","journal-title":"BMJ Open"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.33590\/emj\/21-00017","article-title":"The Safety of Medications During Pregnancy and Lactation in Patients with Inflammatory Rheumatic Diseases","author":"J-W Kim","year":"2021","journal-title":"EMJ Rheumatology"},{"issue":"10","key":"ref111","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"M G Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"104488","DOI":"10.1016\/j.msard.2022.104488","article-title":"Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in S\u00e3o Paulo, Brazil","volume":"70","author":"G D Silva","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"01","key":"ref113","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"T K\u00fcmpfel","year":"2024","journal-title":"J Neurol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"104508","DOI":"10.1016\/j.msard.2023.104508","article-title":"Therapeutic strategies in NMOSD and MOGAD patients: A multicenter cohort study in Latin America","volume":"71","author":"J I Rojas","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"ref115","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1093\/brain\/awq270","article-title":"Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By Michael O'Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures","volume":"133","author":"A Compston","year":"2010","journal-title":"Brain"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1812471.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T01:19:59Z","timestamp":1762823999000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1812471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":115,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["s00451812471"],"URL":"https:\/\/doi.org\/10.1055\/s-0045-1812471","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}